Ovarian steroid cell tumors: what do we know so far?

Area of Science:

• Gynecologic Oncology
• Endocrinology
• Pathology

Background:

• Steroid cell tumors (SCT) of the ovary are rare neoplasms, hindering comprehensive understanding and research.
• These tumors are frequently hormonally active, often leading to elevated androgen levels and symptoms like virilization.

Purpose of the Study:

• To review and summarize current clinicopathologic and molecular information on ovarian SCT.
• To highlight diagnostic features, clinical behavior, and areas for future research.

Main Methods:

• Review of existing literature on ovarian SCT.
• Analysis of clinicopathologic features, imaging (MRI), and histopathology.
• Summary of available molecular data and proposed predictive criteria.

Main Results:

• SCT typically present in patients aged 20-40, are usually Stage I and unilateral, with variable sizes (average 8.4 cm).
• Microscopically, they show polygonal cells with eosinophilic to clear cytoplasm, consistent with sex cord-stromal differentiation. MRI aids in diagnosis.
• Most SCT are benign; however, a subset (<20%) are malignant. Predictive criteria for adverse outcomes are still being established.

Conclusions:

• Ovarian SCT are rare, hormonally active tumors with a predominantly benign course, but malignant potential exists.
• Molecular characterization is limited, with some evidence of hypoxia-signaling gene mutations in SCT and genomic instability in malignant forms.
• Further multi-institutional studies and molecular profiling are crucial for advancing the understanding and management of ovarian SCT.